Seminal
The magazine and atlas of EU-funded researchA new publication from the web and AI team at Scott Charnley

Atlas / Portugal

Marie Skłodowska-Curie Action · Running

MultiTheranostic Theranostic magnetic nano-based codelivery system for boosting cancer immunotherapy

Coordinator
International Iberian Nanotechnology Laboratory, Portugal
Runs
1 January 2025 to 31 December 2026
Status
Running
EU funding
€173k
Total cost
—
Partners
2 organisations in 2 countries
Type
Marie Skłodowska-Curie Action
Grant agreement
101149210

What the project is doing

In the project's own words, from its summary on CORDIS.

Cancer is a leading cause of death and a major impediment to increasing life expectancy around the globe. Amongst all skin cancers, melanoma is a hard-to-treat disease, owing to its high potential for metastasis, and it remains as one of the most aggressive cancers. Single therapy is not efficient to tackle metastatic melanoma and a combination of therapies is thus emerging as a necessity to efficiently eradicate all cancer cells.

Recently, immunotherapy, in particular immune checkpoint inhibitors (ICI), has become a powerful treatment strategy for cancer. Nevertheless, the physical barriers represented by cellular and non-cellular components of the tumour microenvironment combined with immune escape mechanisms of cancer, hamper an efficient tumour infiltration and patients responsiveness to ICI therapy. In this context, MultiTheranostic aims to develop theranostic nanoparticles for gene therapy-mediated immune checkpoint silencing and chemotherapy, exploiting the properties of magnetic nanoparticles to induce damage locally on the tumour microenvironment by magnetic hyperthermia (MH).

This multimodal theranostic approach, incorporating MRI tracking, is versatile, as it could be also applied to other types of solid tumours. MultiTheranostic objectives are (i) to synthetize and validate a biocompatible magnetic lipid nanoparticle (NPs) incorporating silencing RNA against ICI targets, and chemotherapy (WP1, WP2), (ii) to develop a tissue-engineered (TE) model for screening and monitoring the efficacy of the NPs (WP3), and (ii) to demonstrate the effectiveness of the final drug delivery system as a multimodal theranostic approach for metastatic melanoma (WP4).

With MultiTheranostic the researcher will greatly expand her scientific expertise in the fields of nanotechnology and bioengineering, positioning her as a leading independent researcher, contributing to the advancement of nanomedicine in Europe and beyond.

Topics

Who is involved

OrganisationCityCountryRole
International Iberian Nanotechnology LaboratoryBragaPortugalCoordinator
Fundacio Institut De Bioenginyeria De CatalunyaBarcelonaSpainAssociatedpartner

Source: CORDIS, European Commission. Data of 5 Nov 2026, reused under the Commission's reuse policy. View on CORDIS · Grant DOI